Deng et al. found that Carfilzomib (CFZ) inhibits HCC cells’ growth while inducing ROS generation, endoplasmic reticulum stress, and JNK/p38 MAPK activation [22]. Here, MAPK8 is linked to hepatocellular carcinoma.